Table 3 Demographic, clinical and functional data and biomarker assessment of sarcoidosis patients in relation to High resolution computed tomography (HRCT) evidence of involvement
From: Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis
No lung involvement | Lymph node + micronodular | Macronodular and consolidation | Lung fibrosis | P-value | |
|---|---|---|---|---|---|
N° (%) | 27 (11.8) | 127 (55.9) | 62 (27.1) | 12 (5.6) | |
Male (%) | 10 (39) | 59 (46) | 26 (42) | 2 (16) | 0.2063 |
Age yrs | 57.6 ± 10.1 | 55.1 ± 12.7 | 57.3 ± 12.2 | 53.2 ± 12.7 | 0.5185 |
Smoking history (pack/year) | 7.2 ± 11.7 | 3.8 ± 9 | 3.7 ± 9.1 | 8.2 ± 13.4 | 0.4052 |
• Current (%) | 3 (11) | 7 (5) | 3 (5) | 0 | 0.5357 |
• Former (%) | 8 (29) | 37 (29) | 24 (38) | 3 (25) | 0.5357 |
• Never (%) | 16 (59) | 82 (65) | 35 (56) | 9 (75) | 0.5357 |
Biomarkers determination (basal sampling) | |||||
• Chitotriosidase nmol/ml/h | 196.7 ± 150.9 | 284.2 ± 355.2 | 132.3 ± 119.7 | 666.3 ± 311 | 0.0005 |
• ACE UI/ml | 51.4 ± 22.3 | 63.7 ± 31.3 | 50.1 ± 17.9 | 61.6 ± 26.1 | 0.0047 |
• Lysozyme mg/dl | 4.5 ± 1.7 | 5.9 ± 2.2 | 5.1 ± 1.8 | 6.5 ± 2.4 | 0.0033 |
PFTs | |||||
• FVC l (%) | 3.6 ± 0.9 (107 ± 18) | 3.4 ± 1.1 (100 ± 19) | 3.5 ± 1.1 (108 ± 15.3) | 2.7 ± 1.1 (79.3 ± 15.8) | <0.0001 |
• FEV1 l (%) | 2.8 ± 0.8 (100.7 ± 18.7) | 2.6 ± 0.9 (93.3 ± 19.8) | 2.6 ± 0.9 (94 ± 15.6) | 2.1 ± 0.8 (74.5 ± 17.3) | 0.0013 |
• FEV1/FVC | 77.2 ± 5.8 | 76.2 ± 8.6 | 75.1 ± 5 | 78.1 ± 8.2 | 0.3125 |
• TLC l (%) | 6.2 ± 1.3 (109 ± 15.8) | 6 ± 1.5 (105 ± 16.7) | 6.2 ± 1.4 (115.4 ± 18.5) | 4.6 ± 1.6 (91.5 ± 17.2) | 0.0575 |
• DLCO % | 85.3 ± 16.1 | 77.5 ± 14.9 | 79.5 ± 17.6 | 50.4 ± 16.2 | <0.0001 |
• KCO % | 96.3 ± 13.5 | 91.6 ± 19.3 | 89.2 ± 15.6 | 74.7 ± 17.8 | 0.0026 |
Clinical assessment | |||||
• No symptoms (%) | 18 (66) | 44 (35) | 17 (27) | 2 (16) | 0.0018 |
• Cough (%) | 3 (11) | 36 (28) | 16 (26) | 4 (33) | 0.2981 |
• Dyspnea (%) | 4 (15) | 54 (43) | 21 (34) | 8 (66) | 0.0074 |
• Asthenia (%) | 4 (15) | 39 (31) | 16 (26) | 5 (41) | 0.2497 |
• Arthtralgia (%) | 2 (7) | 32 (25) | 25 (40) | 4 (33) | 0.0118 |
Clinical onset | |||||
• Asymptomatic (%) | 24 (89) | 72 (57) | 47 (76) | 10 (83) | 0.0017 |
• Lofgren syndrome (%) | 1 (3) | 8 (6) | 4 (6) | 0 | 0.7808 |
Clinical phenotypes | |||||
• Abdominal (%) | 1 (3) | 14 (11) | 1 (1.6) | 2 (16) | 0.5170 |
• OCCC (%) | 2 (7) | 7 (5) | 3 (5) | 0 | 0.5170 |
• Muscoloskeletal-cutaneous (%) | 3 (11) | 16 (12.6) | 9 (14) | 1 (8) | 0.5170 |
• Isolated pulmonary (%) | 21 (77) | 88 (69.2) | 48 (77) | 9 (75) | 0.5170 |
• Extrapulmonary (%) | 0 | 2 (1.5) | 1 (1.6) | 0 | |
COS classification | 19 | 95 | 51 | 10 | |
• 1 (%) | 4 (21) | 1 (1) | 0 | 0 | 0.0002 |
• 2 (%) | 3 (16) | 3 (3) | 0 | 0 | 0.0002 |
• 3 (%) | 2 (10) | 3 (3) | 0 | 0 | 0.0002 |
• 4 (%) | 2 (10) | 3 (3) | 3 (6) | 0 | 0.0002 |
• 5 (%) | 1 (5) | 4 (4) | 3 (6) | 0 | 0.0002 |
• 6 (%) | 1 (5) | 9 (9) | 9 (17) | 2 (20) | 0.0002 |
• 7 (%) | 4 (21) | 26 (21) | 10 (19) | 1 (10) | 0.0002 |
• 8 (%) | 2 (10) | 36 (36) | 22 (43) | 5 (50) | 0.0002 |
• 9 (%) | 0 | 11 (11) | 4 (8) | 2 (20) | 0.0002 |